Oncotelic Therapeutics annual revenue
2012
2013
2020
2022
2023
2024
2025
Oncotelic Therapeutics Revenue Growth & History (OTLC)
Oncotelic Therapeutics reported $0 in revenue for fiscal 2025.
View full Oncotelic Therapeutics company overviewOncotelic Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | $0 | — |
| 2024 | 2024-12-31 | $0 | −$70,000 | −100.00% |
| 2023 | 2023-12-31 | $70,000 | $70,000 | — |
| 2022 | 2022-12-31 | $0 | — | — |
| 2020 | 2020-12-31 | $1.7M | — | — |
| 2013 | 2013-12-31 | $95,000 | −$61,000 | −39.10% |
| 2012 | 2012-12-31 | $156,000 | — | — |
Oncotelic Therapeutics quarterly revenue
Q1.12
Q2.12
Q3.12
Q4.12
Q3.13
Q1.20
Q2.20
Q3.20
Q4.20
Q3.23
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $250,000 | $250,000 | — |
| Q1 2026 | 2026-03-31 | $0 | $0 | — |
| Q4 2025 | 2025-12-31 | $0 | — | — |
| Q3 2025 | 2025-09-30 | $0 | — | — |
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q1 2025 | 2025-03-31 | $0 | — | — |
| Q3 2023 | 2023-09-30 | $70,000 | — | — |
| Q4 2020 | 2020-12-31 | $0 | — | — |
| Q3 2020 | 2020-09-30 | $0 | — | — |
| Q2 2020 | 2020-06-30 | $1.4M | — | — |
| Q1 2020 | 2020-03-31 | $340,855 | — | — |
| Q3 2013 | 2013-09-30 | $95,000 | $95,000 | — |
| Q4 2012 | 2012-12-31 | $42,000 | — | — |
| Q3 2012 | 2012-09-30 | $0 | — | — |
| Q2 2012 | 2012-06-30 | $0 | — | — |
| Q1 2012 | 2012-03-31 | $114,000 | — | — |
Oncotelic Therapeutics revenue growth trends
Oncotelic Therapeutics's latest reported quarter, Q2 2026, generated $250,000 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Oncotelic Therapeutics source filings ↗